REFLAB ApS: Financial statements 2023
CVR: 15322586
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
REFLAB ApS (CVR 15322586) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 3,455,886 and a net result of DKK -935,624 compared with DKK -646,473 the year before. That is an increase of 7.4% compared with the year before. Equity in the 2023 report amounted to DKK 504,805. The solvency ratio was 8.7%. The company had 7 employees in the financial year.
- Gross Profit
- DKK 3,455,886
- Profit/Loss
- DKK -935,624
- Equity
- DKK 504,805
- Total Assets
- DKK 5,811,408
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 3.5 mio. | -936 t. | 505 t. | 7 |
| 2022 | - | 3.2 mio. | -646 t. | 1.4 mio. | 7 |
| 2021 | - | 3.4 mio. | -341 t. | 2.1 mio. | 7 |
| 2020 | - | 1.9 mio. | -888 t. | 2.4 mio. | 6 |
| 2019 | - | 6.9 mio. | 3.1 mio. | 3.3 mio. | 6 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
REFLAB ApS has published its annual report for 2022. Gross profit came to DKK 3,217,192, and the net result was DKK -646,473.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.